NCT06458595View on ClinicalTrials.gov

Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 28, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

December 28, 2026

Conditions
Age-related Macular Degeneration
Interventions
DRUG

KH658

KH658 Ophthalmic Injection

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Chengdu Origen Biotechnology Co., Ltd.

INDUSTRY